1-3 of 3
Rahul S. Vedula
Close
Sort by
Journal Articles

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Clinical Trials & Observations
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, Jada L. Garzon, Ilene Galinsky, Emilie W. Baxter, Rebecca Leonard, Daniel J. DeAngelo, Marlise R. Luskin, Christopher R. Reilly, Maximilian Stahl, Richard M. Stone, Rahul S. Vedula, Martha M. Wadleigh, Eric S. Winer, Tariq Mughal, Christopher Brooks, Ira V. Gupta, Kristen E. Stevenson, Donna S. Neuberg, Siyang Ren, Julia Keating, Marina Konopleva, Anthony Stein, Naveen Pemmaraju
Journal: Blood Advances
Blood Adv (2024) 8 (3): 591–602.
https://doi.org/10.1182/bloodadvances.2023011721
Published: 2024
Includes: Supplemental data
Journal Articles

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Jurjen Versluis, Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Mark Faber, Rahul S. Vedula, Anne Charles, Kevin M. Copson, Shai Shimony, Alon Rozental, Pavan K. Bendapudi, Ofir Wolach, Elizabeth A. Griffiths, James E. Thompson, Richard M. Stone, Daniel J. DeAngelo, Donna Neuberg, Marlise R. Luskin, Eunice S. Wang, R. Coleman Lindsley
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2835–2846.
https://doi.org/10.1182/bloodadvances.2021006166
Published: 2022
Includes: Supplemental data
Journal Articles

Somatic GATA2 mutations define a subgroup of myeloid malignancy patients at high risk for invasive fungal disease

Rahul S. Vedula, Matthew P. Cheng, Christine E. Ronayne, Dimitrios Farmakiotis, Vincent T. Ho, Sophia Koo, Francisco M. Marty, R. Coleman Lindsley, Tyler D. Bold
Journal: Blood Advances
Blood Adv (2020) 5 (1): 54–60.
https://doi.org/10.1182/bloodadvances.2020002854
Published: 2020
Includes: Supplemental data